Results of cyclophosphamide and cisplatin combination chemotherapy in patients with ovarian carcinoma.
An unselected group of 30 patients with advanced epithelial ovarian cancer, FIGO stage IIb-IV, was treated with cyclophosphamide (750 mg/m2) and cisplatin (75 mg/m2) both administered intravenously on a single day at a 3-weeks interval (CP). At a median follow-up time of 25 months this treatment had resulted in a remission rate of 73% and an estimated median overall survival time of 29 months, which resembles the results of prospective randomized trials. Major side-effects encountered in our patients were renal toxicity and neurotoxicity requiring termination of chemotherapy with CP in 9 patients. Patients with residual tumor smaller than 1 cm had a significant survival benefit as compared to patients with residual tumor greater than 1 cm. Also, patients with stage III ovarian cancer had a significant longer duration of survival than patients with stage IV disease. After a median period of chemotherapy of 7 monthly the median time without symptoms of progression and without treatment was 9 months for patients with an objective remission. We found the CP regimen to be the best therapy to hand: improvement of the prognosis might be attained by other new treatment modalities.
Tibben
J G
JG
Department of Obstetrics and Gynecology, University Hospital Nijmegen, The Netherlands.
Schijf
C P
CP
Beex
L V
LV
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002278:Carcinoma in Situ / Q000188:drug therapy* / Q000401:mortality; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality; D016019:Survival Analysis; D016896:Treatment Outcome
D003520:Cyclophosphamide; D002945:Cisplatin